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AU : Pleaseconfirmthatallheadinglevelsarerepresentedcorrectly:Innovations for undernourished pregnant wom n that improve newborn survival and anthro-
pometry are needed to achieve the Sustainable Development Goals 1 and 3. This study
tested the hypothesis that a combination of a nutritious supplementary food and several
proven chemotherapeutic interventions to control common infections would increase new-
born weight and length in undernourished pregnant women.
Methods and findings
This was a prospective, randomized, controlled clinical effectiveness trial of a ready-to-use
supplementary food (RUSF) plus anti-infective therapies compared to standard therapy in
undernourished pregnant women in rural Sierra Leone. Women with a mid-upper arm cir-
cumference (MUAC)�23.0 cm presenting for antenatal care at one of 43 government health
clinics in Western Rural Area and Pujehun districts were eligible for participation. Standard
of care included a blended corn/soy flour and intermittent preventive treatment for malaria in
pregnancy (IPTp). The intervention replaced the blended flour with RUSF and added azi-
thromycin and testing and treatment for vaginal dysbiosis. Since the study involved different
foods and testing procedures for the intervention and control groups, no one except the
authors conducting the data analyses were blinded. The primary outcome was birth length.
Secondary outcomes included maternal weight gain, birth weight, and neonatal survival.
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Follow-up continued until 6 months postpartum. Modified intention to treat analyses was
undertaken. ParticipantsAU : PerPLOSstyle; subjectsshouldnotbeusedforhumanpatients:Therefore; subjectshasbeenchangedtoparticipantsthroughoutthearticle:Pleaseconfirmthatthischangeisvalid:were enrolled and followed up from February 2017 until February
2020.
Of the 1,489 women enrolled, 752 were allocated to the intervention and 737 to the stan-
dard of care. The median age of these women was 19.5 years, of which 42% were primigra-
vid. Twenty-nine women receiving the intervention and 42 women receiving the standard of
care were lost to follow-up before pregnancy outcomes were obtained. There were 687 sin-
gleton live births in the intervention group and 657 in the standard of care group. Newborns
receiving the intervention were 0.3 cm longer (95% confidence interval (CI) 0.09 to 0.6; p =
0.007) and weighed 70 g more (95% CI 20 to 120; p = 0.005) than those receiving the stan-
dard of care. Those women receiving the intervention had greater weekly weight gain (mean
difference 40 g; 95% CI 9.70 to 71.0, p = 0.010) than those receiving the standard of care.
There were fewer neonatal deaths in the intervention (n = 13; 1.9%) than in the standard of
care (n = 28; 4.3%) group (difference 2.4%; 95% CI 0.3 to 4.4), (HR 0.62 95% CI 0.41 to
0.94, p = 0.026). No differences in adverse events or symptoms between the groups was
found, and no serious adverse events occurred. Key limitations of the study are lack of ges-
tational age estimates and unblinded administration of the intervention.
Conclusions
In this study, we observed that the addition of RUSF, azithromycin, more frequent IPTp, and
testing/treatment for vaginal dysbiosis in undernourished pregnant women resulted in mod-
est improvements in anthropometric status of mother and child at birth, and a reduction in
neonatal death. Implementation of this combined intervention in rural, equatorial Africa may




Why was this study done?
• Undernutrition in pregnancy increases the risk of adverse pregnancy outcomes.
• Interventions for undernutrition in pregnancy have been traditionally based on nutri-
tional supplementation with modest improvement.
• Pregnant women with undernutrition are at increased risk of infection and
inflammation.
• The effect of bundling nutritional and anti-infective interventions for undernutrition in
pregnancy has not been implemented in a clinical trial.
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Consolidated Standards of Reporting Trials; HR,
hazard ratio; IPTp, intermittent preventive
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upper arm circumference; RDA, recommended
daily allowance; RUSF, ready-to-use
supplementary food; SGA, small-for-gestational
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What did the researchers do and find?
• We performed a randomized, controlled clinical trial of a ready-to-use supplementary
food (RUSF) plus anti-infective therapies compared to standard therapy for undernour-
ished pregnant women in rural Sierra Leone.
• Infants born to women receiving the intervention had longer birth lengths, larger
weights, and larger mid-upper arm circumferences (MUACs) when compared to infants
born to mothers receiving the standard of care.
• Mortality was decreased among infants born to mothers receiving the intervention
through 6 months of life.
• Women receiving the intervention had increased weight gain and greater recovery from
undernutrition when compared to women receiving the standard of care.
What do these findings mean?
• Bundling nutritional and anti-infective interventions for the treatment of undernour-
ished pregnant women improved infant birth size, growth, and survival through 6
months of life.
• Futher studies are required to determine the effect of the intervention on preterm birth.
Introduction
Undernutrition in pregnancy is associated with serious adverse risks for mothers and their
unborn children. Maternal undernutrition occurs in 24% of pregnancies in sub-Saharan Africa
[1]. Maternal undernutrition can be reliably identified by mid-upper arm circumference
(MUAC). Maternal MUAC <23.0 cm is associated with increased risk of small-for-gestational
age (SGA) infants [2–4]. The risk of childhood stunting and wasting is increased in SGA
infants [5].
Effective management of maternal undernutrition could improve child survival, growth,
and development [6–8]. Dietary supplements targeted to undernourished pregnant women
have demonstrated modest clinical success [9–11]. Supplementary food increases maternal
weight gain. Ready-to-use supplementary foods (RUSFs) may be superior because they also
decrease the incidence of SGA and low birth weight in some contexts [11,12].
Reduction in exposures that provoke maternal inflammation also improve newborn
growth. Common inflammatory stimuli in Sierra Leone and sub-Saharan Africa include
malaria, sexually transmitted infections, and gut parasite infestation. Plasmodium falciparum
infection is especially deleterious in pregnancy because of its tropism for the placenta, leading
to stillbirth, SGA, and premature delivery [13,14]. Reduction in malaria exposure has been
achieved by the use of insecticide-treated bednets and intermittent preventive treatment for
malaria in pregnancy (IPTp) with sulfadoxine-pyrimethamine (SP) during the second and
third trimesters [15]. Treatment of helminth infections is safe, reduces anemia, and potentially
impacts congnitive and motor function in the offspring [16–19]. Interventions to reduce
malaria and helminth exposure are recommended for all at-risk pregnant women by WHO.
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Azithromycin is a broad-spectrum antibiotic with activity against Chlamydia trachomatis,
Neisseria gonorrhea, Haemophilus ducreyi, and malaria. Azithromycin given during pregnancy
reduced stunting, premature delivery, and postneonatal mortality; sustained improvements in
growth and neurodevelopment were seen at 5 years of age in Malawi [20–22]. Bacterial vagino-
sis is a dysbiosis found in 38% to 51% of pregnant women in sub-Saharan Africa, and its pres-
ence is associated with preterm labor [23]. The dysbiosis resolves with the administration of
metronidazole, and there is evidence to support testing and treatment of women in popula-
tions at high risk for preterm delivery [24,25].
This clinical trial, conducted in Sierra Leone, tested the hypothesis that a combination of an
RUSF, enhanced IPTp, azithromycin administration, and testing and treatment for bacterial
vaginosis when added to the standard of care in undernourished pregnant women improves
newborn length and weight.
Methods
Study design
This was a prospective, randomized, controlled clinical effectiveness trial in undernourished
pregnant women comparing the impact of a package of nutritional and anti-inflammatory
interventions with the standard of care in Sierra Leone. The primary outcome was birth length
in a liveborn singleton pregnancy.
A sample size of 1,514 undernourished pregnant women, divided equally between interven-
tion and the standard of care, was estimated to allow for a 20% lost to follow-up and/or exclu-
sion rate, leaving a final sample size of 1,200 (600 per group) with a two-tailed significance of
0.05, power of 80% to detect a difference of 0.22 SD or 0.5 cm in birth length and a difference
of 0.19 SD or 80 g in birth weight. Full details of the study design and interventions adminis-
tered have been described previously [26]. The study is reported as per the Consolidated Stan-
dards of Reporting Trials (CONSORT) guideline (S1 Fig).
Participants
All pregnant women with undernutrition defined by a MUAC�23 cm and a fundal height
<35 cm as a proxy for duration of gestation were invited to participate from 43 antenatal clin-
ics in Pujehun and Western Rural Area Districts of Sierra Leone. Exclusion criteria were
known gestational diabetes, hypertension, or severe anemia.
Informed consent was obtained for eligible and interested women, and this was docu-
mented by a signature or thumbprint if the participant was unable to write. Women older than
16 years of age were eligible to consent for themselves, and girls younger than the age of 16
desiring to participate required consent from a parent or guardian. Ethical approval was
obtained from the Sierra Leone Ethics and Scientific Review Committee (SLESRC) and from
the Human Research Protection Office at Washington University in St. Louis. The trial was
registered at ClinicalTrials.gov (NCT03079388) on 14 March 2017, 16 days after the first par-
ticipant was enrolled. Late trial registration was the result of very poor 2G internet access at
the study site and a failure of those supporting the trial from abroad to perform this function
while the first author was at the study site.
Randomization and masking
Participants were randomized to intervention or standard of care using a numbered, com-
puter-generated randomization list created for the entire study. A set of opaque envelopes con-
taining each assignment was created from this list. The envelopes were placed in sets of 25,
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those numbered 1 to 25, 26 to 50, 51 to 75 and so forth constituted a set, and eligible women
then selected an envelope from the set to determine their group assignment. No participant
was allowed to choose a second envelope or exchange her envelope after initial selection. All
envelopes in the set currently in use were chosen to assign a participant to a group before a sec-
ond set was brought into use. Further details are available in S1 Text. The RUSF was visually
distinct from flour, so neither the study participants nor the field research study team mem-
bers were masked. Birth outcome assessor and study managers were masked to treatment dur-
ing data collection and analysis.
Participation
The study was conducted in conjunction with care at government-provided antenatal clinics.
Upon enrollment, demographic information, time of last menses, and estimated date of deliv-
ery were recorded. A clinical symptom questionnaire was completed. Weight, height, MUAC,
blood pressure, and fundal height were measured by trained study staff. Weight was measured
with a Seca 803 digital scale (Hamburg, Germany). Height was measured with a Seca stadi-
ometer (Hamburg, Germany). MUAC was measured on the left arm in centimeters to the
nearest 10th of a centimeter with a flexible measuring tape (TALC), according to standard pro-
cedures. Fundal height was measured in the supine position with a nonelastic tape to the near-
est 0.5 cm and used as a proxy for length of gestation [27]. Participants returned for follow-up
every 2 weeks for anthropometric assessment and provision of the study foods and medica-
tions until delivery. Follow-up occurred at 6 weeks, at 3 months, and at 6 months after birth.
Participants were considered lost to follow-up after missing 3 consecutive visits. Home visits
were attempted for any patient lost to follow-up.
Clinic staff and participants were provided a telephone number and credit to call the study
coordinator at the time of delivery. A birth measurement team was dispatched to measure
infants within 48 hours of delivery. Birth measurements were taken as soon as was feasible, but
because of poor road conditions and flooding during rainy season, this was not always possi-
ble. Infant survival, weight, length, head circumference, MUAC, morbidity, and feeding prac-
tices were assessed at each visit. Nude weight was obtained using Seca 334 infant digital scale
(Hamburg, Germany) accurate to 5g. Recumbent length was measured in triplicate using a
Seca 417 rigid height board (Hamburg, Germany); if the measurements differed by 2 mm, a
fourth measurement was taken and the 3 closest measurements were recorded and averaged.
Head circumference and MUAC of the left arm was obtained using a standard tape following
standard procedures to the nearest 1 mm. Maternal weight, MUAC, and morbidity were
assessed at these visits as well. If an infant was identified as deceased, an attempt was made to
identify the cause of death by interviewing the mother and review of the medical record.
Interventions
The RUSF development and production have been previously described [26]. Briefly, linear
programming was used to optimize the RUSF for nutrient content, cost, and inclusion of
indigenous ingredients. Four candidate formulations were tested for acceptability in antenatal
clinics in Pujehun, Sierra Leone. The preferred formulation, named Mama Dutasi, contained
skimmed milk powder, whey protein isolate, vegetable oil, sugar, peanut paste, and pearl mil-
let. The daily RUSF ration provided 520 kcal, 18 g protein, and at least 100% of recommended
daily allowance (RDA) for most micronutrients during pregnancy (S1–S3 Tables). The micro-
nutrient premix included in the RUSF provided the same quantities of micronutrients as the
UNICEF/WHO/United Nations multiple micronutrient supplement for pregnant and lactat-
ing women (UNIMMAP) with additional calcium and magnesium. The RUSF was produced
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by Project Peanut Butter, Sierra Leone. Each batch of food met UNICEF specifications for afla-
toxin, Enterobacter sp., and Salmonella contamination. The standard of care group received
250 g/d of corn/soy blended flour (SuperCereal, World Food Programme) and 25 g palmolein
oil daily. This provided 589 kcal, 17.5 g protein for the participant and as well as a ration for
family sharing as is standard WFP practice. They also received 60 mg iron given as ferrous sul-
fate and 400 μg folic acid. Nutritional supplementation was initiated at the time of enrollment
and continued until the time of delivery. Adherence with nutritional intervention was assessed
at each visit using a standardized questionnaire.
The intervention group received 1,500 mg/75 mg of SP given every 4 weeks beginning in
the second trimester. The standard of care group received 3 doses of 1,500 mg/75 mg SP dur-
ing second and third trimesters.
The intervention group received 1 g of azithromycin at the beginning of the second trimes-
ter and in the third trimester. The intervention group was tested for vaginal dysbiosis upon
enrollment and again in the third trimester using rapid sialidase testing (OSOM BVBLUE,
Sekisui Diagnostics, Burlington, MA, USA). If dysbiosis was found, participants were treated
with 500 mg metronidazole twice daily for 7 days.
All participants received an insecticide-treated bednet and 400 mg of albendazole in the sec-
ond trimester of pregnancy. Doses of SP for IPTp, azithromycin, and albendazole were given
under direct observation during study visits. Only the first dose of metronidazole was adminis-
tered under direct observation. The study assured uninterrupted access to study food and
medicine for the duration of their pregnancy.
Outcomes
The primary outcome was newborn length. Secondary outcomes were the total and average
weekly maternal weight gain, fundal height at delivery, recovery from maternal undernutrition
defined as a MUAC >23 cm, newborn weight and head circumference, infant linear and
ponderal growth through 6 months, and infant survival at 1.5, 3, and 6 months.
Statistical analyses
Data were first recorded on clinic management cards. Data from these cards were then double
entered into a spreadsheet database (Microsoft Access) and cross checked for discrepancies.
All discrepancies were resolved by examination of the original data card. Once the content of
the database was determined, it was locked for analyses.
Descriptive statistics were used to characterize the study population. Mothers with single-
ton live births were included in the modified intention-to-treat comparative analyses. All sin-
gleton live birth data were included in the primary comparison, regardless of maternal
duration of participation or adherence. Those lost to follow-up prior to delivery could not be
included. All anthropometric parameters were converted to z-scores using the 2006 WHO
growth standards [28]. Two-sided independent samples Student t test was used to compare
continuous outcomes (IBM SPSSS Statistics v. 25, IBM, Armonk, NY, USA). Mean differences
with 95% confidence intervals (CIs) were calculated. A p-value of<0.05 was considered statis-
tically significant for hypothesis testing. Fisher exact test was used to compare categorical out-
comes, and Newcombe/Wilson score with continuity correction was used to calculate 95% CIs
for differences in the proportions.
Linear mixed effects analysis of the relationship of the intervention and maternal and infant
anthropometrics over the study period was performed in R (version 3.6.0) and lme4 package.
For maternal anthropometric analysis, fixed effects of study group, duration of enrollment,
and their interaction were entered with individual participant variability accounted for as a
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random variable. For analysis of infant anthropometrics as fixed effects, we entered whether
the mother/newborn dyad received the intervention or control, age at measurement, and sex,
and their interaction with individual participant variability accounted for as a random vari-
able. p-values were estimated via t tests using the Satterthwaite approximations to degrees of
freedom.
Time–event analysis was performed to compare infant survival up to 6 months of age
between the groups. The Cochran–Mantel–Haenszel test was used to calculate hazard ratios
(HRs). Statistical analysis was performed using IBM SPSS Statistics v. 25 (IBM, Armonk, NY,
USA), R (version 3.6.0), and GraphPad Prism version 8.3.0 (GraphPad, San Diego, CA, USA).
Results
Of theAU : PleaseconfirmthattheeditstothesentenceOfthe1; 489womenenrolledinthestudyfromFebruary:::didnotaltertheintendedthoughofthesentence:1,489 wom n en olled in the study from February 2017 to May 2019, 752 were allocated
to the intervention group and 737 to the standard of care group (Fig 1). The numbers of
women that defaulted were low with 29 (3.9%) receiving the intervention and 42 (5.7%) receiv-
ing the standard of care (Table 1). The duration of participation was 15.4 weeks (Q1:10,
Q3:21) for the intervention and 14.9 weeks (Q1:9.3, Q3:20) for the standard of care (median
difference 0.5; 95% CI −0.29 to 1.43).
There were no serious adverse events during the study period and no statistically significant
differences in adverse events/symptoms between the groups (S4 Table). Adherence with the
study foods was high in both groups as assessed by surveys (S5 Table). Adherence with IPTp
was high with women in the intervention group receiving a mean of 4.4 doses (SD 1.4) and
women in the standard group receiving 2.8 doses (SD 0.6) (S6 Table). Azithromycin adherence
was good among women in the intervention group with 473 (68.9) receiving 2 doses and
210 (30.6%) receiving 1 dose prior to delivery. The timing of last azithromycin administration
was on average 8.2 (SD 3.8) weeks before delivery. There were no differences in the
number of maternal deaths, miscarriages, or stillbirths (S7 Table). There were 687 (91.5%) sin-
gleton live births in the intervention group and 657 (89.2%) in the standard of care group
(p = 0.136).
When compared to women receiving the standard of care, women receiving the interven-
tion had greater total weight gain, weekly weight gain, larger MUAC gain from enrollment,
and had a 7.2% higher rate of recovery from undernutrition at final study visit (Table 2). The
number needed to treat for one woman to recover from undernutrition was 13.9 (95% CI 8.3
to 44.2) Fewer women in the intervention group than the standard of care group delivered
with fundal height<37 cm (difference 10.5%; 95% CI 06.3 to 14.6, P� 0.001) (Table 2,
S1 Fig).
Using linear mixed modeling, the intervention was shown to increase weight gain from
enrollment when the duration of participation was included as a covariate resulting in an
increase of 30 grams (SE 10) of weight gain per week of enrollment (p =<0.001; 95% CI 20 to
40) (S8 Table). MUAC change was increased in women in the intervention group when com-
pared to standard of care. Over the course of enrollment, women in the intervention group
gain 0.1 cm (SE 0.04) more in MUAC (p =<0.001; 95% CI 0.1 to 0.2) or 0.01 cm (SE 0.002)
per week enrolled (p =<0.001; 95% CI 0.01 to 0.01) (S8 Table).
When evaluating postpartum maternal outcomes, linear mixed modeling demonstrated a
significant effect of the study group and time since birth on maternal weight with mothers in
the intervention group weighing 0.81 kg (SE 0.28) more than mothers in the standard of care
group (p = 0.003; 95% CI 0.27 to 1.36) (S9 Table). The effect of the intervention appeared to
wane with time since birth. Maternal postpartum MUAC was not significantly different
between women in the 2 groups (S9 Table).
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Among singleton live births, there were 657 infants in the intervention and 621 in the stan-
dard of care groups with available birth data. Birth measurements were obtained at median of
1.0 days (Q1:1.0 and Q3:3.0) both the intervention group and the standard of care group
(median difference 0.0; 95% CI 0 to 0; p = 0.968). Infants born to mothers in the intervention
group were 0.3 cm longer (95% CI 0.09 to 0.6; p = 0.007), weighed 70 g more (95% CI 20 to
120; p = 0.005), and had MUACs that were 0.1 cm larger (95% CI 0.03 to 0.2; p = 0.006) than
infants born to mothers receiving the standard of care (Table 3).The effect size remained the
same for birth length when only infants measured within 7 days were considered (0.3 cm; 95%
CI 0.002 to 0.5; p = 0.049) (S10 Table). Among the 41 participants with missing birth data, 19
(46%) were in the intervention group and 22 (54%) were in the standard of care group. Of the
113 infants with birth data collected after 7 days of life, 62 (55%) were in the intervention
group and 51 (45%) were in the standard of care group.
Linear mixed models demonstrated an effect of age at measurement, sex, and study group
on the length, weight, and MUAC of infants born to mothers in the study (S11 Table). Infants
in the intervention group were 0.3 cm (SE 0.1) longer than those in the standard of care group
(p = 0.011; 95% CI 0.1 to 0.5) and 85g (SE 33) heavier than those in the standard of care group
(p = 0.01; 95% CI 20 to 150) (S11 Table). Infant head circumference was not different between
infants born to mothers in the 2 study groups.
Fig 1. CONSORT flow diagram. “Lost to follow-up” refers to individuals who were not seen at the time point indicated and subsequently never seen again.
“Visit data unavailable” refers to individuals who were not seen at the time point indicated but subsequently seen. Deaths are reported as additional deaths
between each time point.
https://doi.org/10.1371/journal.pmed.1003618.g001
Table 1. Enrollment characteristics1.
Characteristic Intervention n = 751 Standard n = 737
Age2, year 21.0 ± 4.7 21.5 ± 4.9
Age2, median (range) 19.0 (13–40) 20.0 (14–42)
Participant <18 years of age 294 (40) 244 (34)

















MUAC, cm 22.3 ± 0.7 22.3 ± 0.8
Weight3, kg 48.1 ± 5.0 47.8 ± 4.9
Fundal height4, cm 23 ± 7 24 ± 6
Baseline height5, cm 155.8 ± 7.2 155.6 ± 6.4
Height <145 cm 30 (4) 29 (4)
HIV-infected6 25 (5) 26 (5)
MUAC, mid-upper arm circumference.
1Values expressed as mean ± SD or n (%).
2Age was unknown for Intervention n = 21 and Standard n = 24 participants.
3Initial weight missing in Intervention n = 2.
4Fundal height unmeasurable in Intervention n = 64, Standard n = 54.
5Baseline height missing in Intervention n = 4 and Standard n = 1.
6HIV status unknown in Intervention n = 235 and Standard n = 219.
https://doi.org/10.1371/journal.pmed.1003618.t001
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There were fewer infant deaths in the intervention group (35; 5.6%) than in the standard of
care group (53; 8.9%; difference 3.3%, 95% CI 0.3% to 6.4%, p = 0.027) in the first 6 months of
life (S12 Table). The number needed to treat for infant survival benefit was 29.99 (95% CI
15.68 to 463.2). The HR for death among infants born to mothers in the intervention group
was 0.62 (95% CI 0.41 to 0.94, p = 0.026) (Fig 2). The mortality benefit occurred during the
neonatal period (�21 days) when there were 13 (1.9%) deaths among the intervention group
infants and 28 (4.3%) deaths among the standard of care group infants (difference 2.4%, 95%
CI 0.3 to 4.4, p = 0.016; HR 0.44, 95% CI 0.23 to 0.82, p = 0.011) (S12 Table).
Among women in the intervention group, 370 (59%) tested positive for bacterial vaginosis.
Among the 293 who had repeat testing prior to delivery, 217 (74%) remained positive for bac-
terial vaginosis despite treatment. There were no significant differences in pregnancy or
growth outcomes between women testing positive and receiving treatment and those testing
negative, except for increased maternal weight and MUAC gain in those testing negative and a
slightly larger infant head circumference (S13 and S14 Tables).
The intervention cost an additional $13.86 per woman plus $0.21 per day for the RUSF
when compared to the standard of care. This cost included testing for vaginal dysbiosis, which
was $11.07.
Discussion
In this study, we observed that infants born to undernourished women receiving the package
of RUSF with a combination of anti-infective interventions were slightly longer and heavier, as
well as more likely to survive the neonatal period when compared to those receiving the
Table 2. Maternal outcomes for mothers with singleton live births, by treatment group1.
Outcome Intervention n = 687 Standard of Care n = 657 P Mean Difference (95% CI)
Weeks enrolled2 15.4 (Q1:10, Q3:21) 14.9 (Q1:9.3, Q3:20) 0.183 0.5(−0.29 to 1.43)
MUAC at final antenatal visit, cm 22.8 ± 1.0 22.6 ± 1.2 0.005 0.17(0.05 to 0.28)
Change in MUAC, cm 0.5 ± 0.8 0.4 ± 0.9 0.015 0.11(0.02 to 0.20)
Weight at final antenatal visit, kg 53.68 ± 5.11 52.56 ± 5.08 <0.001 1.12(0.57 to 1.66)
Total weight gain, kg3 5.36 ± 3.75 4.69 ± 3.67 0.001 0.67(0.27 to 1.06)
Average weekly weight gain, g3 379 ± 222 339 ± 333 0.010 40(10 to 71)
Weight gain <454 g/week3 457(68.7) 477(75.0) 0.014 6.3%(1.3 to 11.3)
Final fundal height4, cm 36.1 ± 2.6 35.6 ± 2.9 0.007 0.4(0.1 to 0.7)
Final fundal height <37 cm5 528(77.3) 574(87.7) <0.001 10.5%(6.3 to 14.6)
Final fundal height <28 cm4 11(1.6) 16(2.4) 0.277 0.8%(−0.9 to 2.5)
Final fundal height 28 to 32 cm4 62(9.1) 85(13.0) 0.022 3.9%(0.4 to 7.4)
Final fundal height 32 to 37 cm4 455(66.6) 473(72.3) 0.024 5.7%(0.7 to 10.8)
MUAC at delivery6, cm 22.5 ± 1.0 22.3 ± 1.2 <0.001 0.2(0.1 to 0.4)
Recovered from undernutrition6 198(29.9) 142(22.7) 0.004 7.2%(2.3 to 12.0)
MUAC, mid-upper arm circumference.
1Values expressed as mean ± SD or n (%); p-values calculated using independent t test (continuous measures), Fisher exact test, or chi-squared test (categorical
measures). For outcomes reported as numbers and percentages of participants, the difference is given as the percentage–point difference between groups.
2Values expressed as median (quartiles); p-value calculated using Mann–Whitney U test.
3Initial weight unavailable in Intervention n = 1. Only 1 study visit Intervention n = 21, Standard n = 21.
4Final fundal height not available for Intervention n = 4 and Standard n = 3.
5Fundal height was used as a crude marker for gestational age. Birth <28 weeks is considered extremely preterm, 28 to 32 weeks is very preterm, and 32 to 37 weeks is
late preterm.
6MUAC a delivery not available for Intervention n = 24 and Standard n = 31.
https://doi.org/10.1371/journal.pmed.1003618.t002
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standard of care. Women receiving the intervention had greater weight gain when compared
to those receiving the standard of care.
Other trials of combined nutritional and anti-infective interventions in undernourished
pregnant women have not been reported to our knowledge.
The RUSF included milk as an ingredient; increased milk intake has been associated with
increased birth weight [29–31]. RUSF is a balanced protein energy supplement, providing
ample amounts of micronutrients and substantial quantities of essential amino acids required
in pregnancy that were not provided in the blended flour provided to the standard of care
group. Balanced protein energy supplementation has demonstrated modest increases in birth
weight when provided to undernourished pregnant women [9,32]. A similar effect on birth
length has been observed in some, but not all, trials distributing nutritional supplementation
to undernourished pregnant women in Africa [9,33].
Neonatal deaths were reduced by the combined intervention. The major causes of neonatal
deaths in this setting are prematurity, complications of delivery, and infant infection [34]. Azi-
thromycin targets the ribosomal subunit of susceptible microbes, inhibiting protein synthesis
and causing microbial death. Ureaplasma infections of the placenta are common, asymptom-
atic, associated with preterm birth and SGA newborns, and are effectively treated with azithro-
mycin [35]. In Sierra Leone, malaria parasitemia in children under 5 years is about 47%,
without significant seasonal variation [36]. Azithromycin has anti-inflammatory properties
that may work to control maternal inflammation and improve fetal growth [37–40]. Azithro-
mycin administration also results in alterations in the gut microbiome and perhaps may
remove pro-inflammatory flora from the microbiota as a mechanism of action [41]. The most
Table 3. Singleton infant outcomes, by treatment group1.
Intervention Standard
Outcome Value Value P Mean Difference (95% CI)








n = 657 n = 621
Birth length, cm 47.2 ± 2.2 46.9 ± 2.5 0.007 0.3(0.1 to 0.6)
Birth weight, kg 2.87 ± 0.44 2.80 ± 0.44 0.005 0.07(0.02 to 0.12)
Birth head circumference, cm 33.9 ± 1.4 33.8 ± 1.6 0.109 0.1(−0.03 to 0.3)
Birth MUAC, cm 9.9 ± 0.8 9.8 ± 0.8 0.006 0.1(0.03 to 0.2)
Birth LFA, z-score1 −1.45 ± 1.06 −1.57 ± 1.16 0.054 0.12(−0.002 to 0.24)
Birth WFL, z-score2 0.03 ± 1.1 −0.01 ± 1.02 0.478 0.05(−0.08 to 0.18)
Birth WFA, z-score −1.01 ± 0.96 −1.15 ± 1.03 0.012 0.14(0.03 to 0.25)
Birth BMI, z-score −0.48 ± 1.11 −0.57 ± 1.03 0.152 0.09(−0.03 to 0.20)
Stunted at birth1, LFA < −2 184(31.1) 188(33.4) 0.414 2.3(−3.2 to 7.8)
Undernourished at birth2, WFL < −2 18(3.0) 16(2.8) 1.00 0.2(−2.5 to 2.7)
Underweight at birth, WFA < −2 80(13.5) 84(14.8) 0.556 1.3(−2.3 to 5.4)
Low birth weight (<2.5 kg) 115(19.5) 126(22.2) 0.248 2.7(−2.0 to 7.6)
BMI, body mass index; LFA, length-for-age z-score; MUAC, mid-upper arm circumference; WFA, weight-for-age z-score; WFL, weight-for-length z-score.
Values expressed as mean ± SD or n (%); p-values calculated using independent t test (continuous measures), Fisher exact test, or chi-squared test (categorical
measures). For outcomes reported as numbers and percentages of participants, the difference is given as the percentage–point difference between groups.
1Infants had length�38.0 cm, too short for LFA z-score, Standard n = 4.
2Infants were excluded from WFL z-score because they were too short (<45.00 cm), Intervention n = 90 and Standard n = 112.
https://doi.org/10.1371/journal.pmed.1003618.t003
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plausible mechanism of action for azithromycin in our study was the reduction of microbes
harbored in the placenta, in particular malaria.
Four large clinical trials have reported the effects of using azithromycin in pregnancy given
many weeks prior to delivery (S15 Table). TwoAU : PleaseconfirmthattheeditstothesentenceTwoofthesewereinMalawi; onethatshowedno:::didnotaltertheintendedthoughtofthesentence:of these were i Malawi, one that showed o
effect on premature delivery, newborn anthropometry, maternal malaria parasitemia, or
Fig 2. Kaplan–Meier survival estimates. Shown is the incidence of death among offspring assigned to the
intervention group and those assigned to the standard of care. Values were calculated with the use of Kaplan–Meier
methods and compared with Mantel–Haenszel test. Panel A demonstrates the survival curve for perinatal and neonatal
mortality. Panel B demonstrates infant mortality from birth until 6 months of life.
https://doi.org/10.1371/journal.pmed.1003618.g002
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perinatal survival [42]. The other Malawian trial demonstrated a reduction in premature deliv-
ery, maternal parasitemia, and low birth weight, with a reduction in infant mortality after the
neonatal period [43]. A third trial from Uganda found reduction in sexually transmitted dis-
eases, low birth weight, and neonatal deaths within 7 days of delivery [44]. The fourth trial
from Papua New Guinea found a reduction in premature delivery, low birth weight, and mul-
tiple measures of malaria infection [45]. The rates of neonatal death were very low in the con-
trol group in the trial from New Guinea. Mass azithromycin distribution reduced child
mortality when given to children in Niger, Tanzania, and Malawi, with the largest effect in
Niger where mortality is the highest [46,47]. Our data add to the multiple lines of evidence
suggesting azithromycin may be an important adjunct to improve child survival.
Concern about the risk for emergence of resistant bacteria with widespread administration
of azithromycin is frequently raised. Though use of azithromycin in pregnancy and labor
increases the number of macrolide-resistant organisms identified in young infants, this resis-
tance wanes after 12 months [48–50]. In undernourished pregnant women, the emergence of
antibiotic resistant strains must be balanced against the opportunity to reduce neonatal death
by 2.3-fold. In this study, azithromycin was first given in the second trimester, as recent epide-
miologic evidence found an increased risk of major malformations in infants born to mothers
prescribed a macrolide in the first trimester [51].
Vaginal dysbiosis did not resolve with metronidazole treatment in most cases. Recurrence
of vaginal dysbiosis after treatment is common and is increased by continued exposure
through sexual activity [52–54]. In other settings, more success in resolution of the dysbiosis
has been seen with transplantation of vaginal secretions [55]. Chronic suppressive therapy has
been demonstrated effective to reduce development or recurrence of bacterialAU : PleasenotethatBVhasbeenexpandedtobacterialvaginosistoenforceconsistencyintheuseofthiswordthroughoutthetext:Pleaseconfirmthatthischangeisvalid:vaginosis,
though this approach cannot be applied broadly to a population without further investigation
and evidence [56].
Vaginal dysbiosis testing and treatment with metronidazole as a component of large-scale
intervention is not supported by our data.
The randomized design that enrolled a common cadre of high-risk pregnant women from a
malaria-endemic, resource-limited setting is the greatest strength of the study. The interven-
tion package was feasible; its elements have been used extensively in clinical settings. The
implementation of the study might serve as an example for future operational programs. All
outcomes were determined using standardized, objective methods, and birth outcomes were
masked. The major limitation of this study was that there was no ultrasound dating of gesta-
tional age. Thus, we cannot determine whether the intervention reduced premature delivery.
The unblinded design of the study introduced the possibility that participants shared their
assigned food; mitigating this risk was that most participants resided more than 2 km apart.
Participants receiving the standard of care may well have had improved outcomes when com-
pared to women receiving typical clinical care, because of sporadic availability of any foods
and medications in the resource-limited setting. The causes of infant death were not ascer-
tained using reliable methods; therefore, conclusions cannot be drawn. The study population
is representative of rural mothers in agrarian, malaria-endemic sub-Saharan Africa, and the
effectiveness of the intervention cannot be reasonably extrapolated to other populations. This
intervention was not given as a blanket distribution for all pregnant women living in a vulnera-
ble environment, but rather targeted to those who were undernourished. Thus, no evidence
for the use of the intervention as a universal public health practice can be inferred.
The intervention cost more when compared to the standard of care, which must be consid-
ered when considering scale-up of the intervention. The opportunity cost to participants
returning to clinic fortnightly was high, but, operationally, food and medication administra-
tion could be done monthly.
PLOS MEDICINE A clinical trial of food and anti-infective interventions in undernourished women in Sierra Leone
PLOS Medicine | https://doi.org/10.1371/journal.pmed.1003618 September 28, 2021 13 / 18
Further studies are required to elucidate the effects of routine prenatal azithromycin on
maternal and infant carriage of resistant organisms.
In conclusion, delivery of a bundled intervention of a nutritious RUSF and enhanced pre-
vention of infection during pregnancy resulted in larger infants, improved maternal recovery
from undernutrition, and improved neonatal survival. The intervention is promising as it
could contribute to Sustainable Development Goal 3.2, reducing neonatal mortality to 25 per
1,000 live births in areas where neonatal death is high as well as risk for malaria infection [57].
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